AR065468A1 - Derivados de nevirapina inhibidores de la transcriptasa reversa - Google Patents

Derivados de nevirapina inhibidores de la transcriptasa reversa

Info

Publication number
AR065468A1
AR065468A1 ARP080100774A ARP080100774A AR065468A1 AR 065468 A1 AR065468 A1 AR 065468A1 AR P080100774 A ARP080100774 A AR P080100774A AR P080100774 A ARP080100774 A AR P080100774A AR 065468 A1 AR065468 A1 AR 065468A1
Authority
AR
Argentina
Prior art keywords
nevirapine
reverse transcript
deuterium
derivatives inhibitors
inhibitors
Prior art date
Application number
ARP080100774A
Other languages
English (en)
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR065468A1 publication Critical patent/AR065468A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la Formula estructural (1) o una sal, solvato, o profármaco farmacéuticamente aceptable del mismo; caracterizado porque: R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, y R14 seseleccionan independientemente del grupo que consiste de hidrogeno y deuterio; al menos uno de R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, y R14 es deuterio; y cuando R3, R4, y R5 son deuterio luego al menos uno de R1, R2, R6, R7, R8,R9, R10, R11, R12, R13, y R14 es deuterio.
ARP080100774A 2007-02-23 2008-02-25 Derivados de nevirapina inhibidores de la transcriptasa reversa AR065468A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89143607P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
AR065468A1 true AR065468A1 (es) 2009-06-10

Family

ID=39615861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100774A AR065468A1 (es) 2007-02-23 2008-02-25 Derivados de nevirapina inhibidores de la transcriptasa reversa

Country Status (4)

Country Link
US (1) US20080241289A1 (es)
AR (1) AR065468A1 (es)
TW (1) TW200835693A (es)
WO (1) WO2008103899A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774999A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011041512A2 (en) * 2009-10-02 2011-04-07 Emory University Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases
DE112010004065T5 (de) * 2009-11-10 2012-10-25 North West University Verfahren zur Erhöhung der Löslichkeit einer Transkriptaseinhibitor-Zusammensetzung
US20120295898A1 (en) 2010-01-27 2012-11-22 Mark Richard Underwood Antiviral Therapy
CN111423456A (zh) * 2020-04-03 2020-07-17 南京昊绿生物科技有限公司 一种利福昔明-d6的合成工艺
WO2021248022A1 (en) * 2020-06-04 2021-12-09 The General Hospital Corporation Methods of treating a coronavirus infection
WO2023010071A1 (en) * 2021-07-28 2023-02-02 University Of Louisville Research Foundation, Inc. Anti-fungal griffithsin compostions and methods of use
CN115028577A (zh) * 2022-06-24 2022-09-09 盐城迪赛诺制药有限公司 一种2-氯-n-（2-氯-4-甲基吡啶-3-基）烟酰胺的提纯方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US20070232532A1 (en) * 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7932235B2 (en) * 2006-11-17 2011-04-26 Concert Pharmaceuticals, Inc. Triazolyl tropane derivatives
WO2008077103A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
WO2008156632A1 (en) * 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20080318904A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched tenofovir
US20090075991A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched efavirenz
US20090076138A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched darunavir
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine

Also Published As

Publication number Publication date
TW200835693A (en) 2008-09-01
WO2008103899A1 (en) 2008-08-28
US20080241289A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
AR065468A1 (es) Derivados de nevirapina inhibidores de la transcriptasa reversa
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
ES2546515T3 (es) Nuevo compuesto péptido cíclico, método para producirlo, agente anti-infeccioso, fracción que contiene antibiótico, antibiótico, método para producir antibiótico, microorganismo productor de antibiótico y antibiótico producido mediante el mismo
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
RS54587B1 (en) IMINOTIADIAZINE-DIOXIDE COMPOUNDS AS BACE, MIXTURE, AND USE INHIBITORS
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
NO20092279L (no) Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
AR073524A1 (es) Piridopirimidinonas inhibidores de pi3k a y m tor
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CL2009000228A1 (es) Compuestos derivados de 7,8-dihidropirido[4,3-d]pirimidin con un sustituyente oximico, inhibidores de hsp90; y composicion farmaceutica que comprene a dichos compuestos.
MX2007016185A (es) Inhibidores de aspartil proteasa heterociclicos macrociclicos.
CO6321230A2 (es) Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
MY151986A (en) Adamantyl diamide derivatives and uses of same
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR063805A1 (es) Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas.
NO20090270L (no) Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister
AR067528A1 (es) Eteres heterociclicos sustituidos y su uso en trastornos del snc

Legal Events

Date Code Title Description
FA Abandonment or withdrawal